FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	. OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MALKIEL BURTON G						2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]									all app	olicable) ctor		Issuer Owner (specify
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 08/11/2017									Officer (give title below)		belov	
(Street) SOUTH SAN FRANCISCO (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv Line) X	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - I	Non-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefic	ially (Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Ac Disposed Of (D)				d 5) Secu Bene Own		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Ī	Code	v	Amount	(A) or (D)	Price			rted action(s) . 3 and 4)		(Instr. 4)	
Ordinary Shares 08/11/202)17	17			P		15,000	A	\$24.59	903(1)	4	47,571	D		
Ordinary Shares			08/11/20	2017				P		15,000	A	\$24.58	377 ⁽²⁾	15,000		I	By Spouse	
		Т	able II								osed of, convertib				ned			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed			ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. Represents the weighted average purchase price per share for the open market purchase on August 11, 2017. The shares were purchased at prices ranging from \$24.35 to \$24.921 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- 2. Represents the weighted average purchase price per share for the open market purchase on August 11, 2017. The shares were purchased at prices ranging from \$24.36 to \$24.903 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Brett A. Grimaud, Attorney-in-08/14/2017 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.